On July 12, Baheal Pharma (301015.SZ) announced the successful acquisition of Shanghai Baheal Pharma Co., Ltd. ("Baheal Pharma Co."), following the completion of business registration changes and handover procedures. Through this acquisition, Baheal Pharma now directly holds 60.199% of Baheal Pharma Co.'s shares, making it the controlling shareholder. As a result, Baheal Pharma Co.'s financial performance and status will be consolidated into Baheal Pharma's financial statements.

Recently, the 2024 Misi Conference (China's Pharmaceutical and Health Industry Synergy Conference), organized by the authoritative pharmaceutical information service platform Menet, opened in Huzhou. At the event, the highly anticipated "2023 Top 100 Chinese Pharmaceutical Companies" list was officially unveiled. Shanghai Huanghai Pharmaceutical Co., Ltd. (henceforth "Shanghai Huanghai Pharmaceutical"), a subsidiary of Shanghai Baheal Pharmaceutical Co., Ltd. (henceforth "Baheal Pharma"), was prominently featured on the "2023 Top 100 Traditional Chinese Medicine Companies" list, thanks to its strong capabilities in modern traditional Chinese medicine research and production.

Baheal Pharmaceutical Co. Ltd., with its headquarters in Shanghai, celebrates as its subsidiary, Qingdao Baheal Pharmaceutical Co. Ltd., has been graced with a flawless report from the US Food and Drug Administration (FDA). The agency's recent inspection concluded with a commendable 'No Action Indicated' (NAI) classification and without a single Form 483 observation - a testament to the company's strict adherence to the Current Good Manufacturing Practice (cGMP) guidelines. This clean bill of health is not the first for Qingdao Baheal Pharmaceutical, which previously achieved a 'zero-deficiency' rating in 2016, solidifying its stellar standing with the FDA.

On May 9, 2024, Baheal Pharma (301015.SZ) introduced a new product under its imported calcium brand, D·Cal: D·Cal Peachy Sachets®. This product innovation focuses on women's bone health needs, providing consumers with a fresh calcium supplementation experience.

On March 28, 2024, the Qingdao High-End Intelligent Manufacturing Industrial Base for Life and Health Technology was officially launched, with a signing ceremony for the first batch of resident companies held in Qingdao's Shibei District. The event featured speeches from Jiang Baoguo, Academician of the Chinese Academy of Engineering and Director of the National Trauma Medical Center, and Geng Tao, Member of the Standing Committee of the Qingdao Municipal Party Committee and Vice Mayor. The event was attended by Bo Tao, Vice Chairman of the Qingdao CPPCC and Director of the Qingdao Municipal Health Commission, along with other key officials from relevant city and district departments, and Fu Gang, Chairman of Baheal Pharma Group. At the ceremony, four innovative companies incubated by Baheal Pharma Group signed agreements to become the first residents of the base. Additionally, the Qingdao Huizhu Baheal Medical and Health Industrial Investment Fund was officially signed.